期刊文献+

^(64)Cu标记生长抑素受体显像剂的研究进展 被引量:1

Progress in Researches on ^(64)Cu-labeled Somatostatin Receptors Imaging Agents
下载PDF
导出
摘要 生长抑素受体在大多数神经内分泌肿瘤细胞表面过表达,可作为很好的靶点用于放射性显像及治疗研究。由于具有良好的核物理性质和生物半衰期,近年来^(64)Cu标记的生长抑素受体显像剂成为神经内分泌肿瘤重要的诊断和治疗工具。在这些靶向肿瘤分子研究中,新型稳定的双功能螯合剂(BFC)起至关重要的作用,同时,非螯合的纳米技术标记方法也成为^(64)Cu标记生物分子的新兴发展趋势。本文对^(64)Cu标记生长抑素受体显像剂的研究发展作一综述。 Somatostatin receptors are overexpressed in a wide range of neuroendocrine tumors, making them excellent targets for nuclear imaging and therapy. With its superior physical properties and biological half-life, 64Cu-labeled somatostatin receptors radiopharmaceuticals become an importantly diagnostic and therapeutic tool in positron emission tomograpby in recent years. Newly stable bifunctional chelators act as an important role in the researching of the somatostatin receptors targeting tumor molecules. Meanwhile, nanotechnology of non-chelated labeling method is becoming a new trend of 64Cu-labeling biological molecules development. This review emphasizes developments of 64Cu-labeled somatostatin receptors imaging agents in the past.
出处 《中国医学计算机成像杂志》 CSCD 北大核心 2015年第4期398-403,共6页 Chinese Computed Medical Imaging
基金 广东省自然科学基金(No.S2012010010685 No.S2013040016926) 广东省教育部产学研结合项目(No.2012B091100172)~~
关键词 64Cu 生长抑素受体显像剂 螯合剂 神经内分泌肿瘤 64Cu somatostatin receptors imaging agent chelator neuroendocrine tumor
  • 相关文献

参考文献19

  • 1Lewis JS, Lewis MR, Srinivasan A, et al. Comparison of four 64Cu-labeled somatostatin analogues in vitro and in a tumor- bearing rat model: evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy. Journal of medicinal chemistry, 1999, 42: 1341-1347.
  • 2Maecke HR, Reubi JC. Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment. Journal of Nuclear Medicine ,2011, 52: 841-844.
  • 3Edwards WB, Xu B, Akers W, et al. Agonist-antagonist dilemma in molecular imaging: evaluation of a monomolecular multimodal imaging agent for the somatostatin receptor. Bioconjugate chemistry, 2008, 19: 192-200.
  • 4Nguyen K, Parry JJ, Rogers BE, et al. Evaluation of copper-64- labeled somatostatin agonists and antagonist in SSTr2-transfected cell lines that are positive and negative for p53: implications for cancer therapy. Nucl Med Biol, 2012, 39: 187-197.
  • 5Wild D, Fani M, Behe M, et al. First clinical evidence that imaging with somatostatin receptor antagonists is feasible. Journal of Nuclear Medicine, 2011, 52: 1412-1417.
  • 6Pfeifer A, Knigge U, Mortensen J, et al. Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2012, 53: 1207-1215.
  • 7Pfeifer A, Knigge U, Binderup T, et al. 64Cu-DOTATATE PET for Neuroendocrine Tumors: a Prospective Head-to-Head Comparison with mIn-DTPA-octreotide in 112 Patients. Journal of nuclear medicine : official publication, Society of Nuclear Medicine,2015, 56: 847-854.
  • 8Folke Pedersen S, Vikjer SandhoR B, Hogild Keller S, et al. 64Cu- DOTATATE PET/MRI for Detection of Activated Macrophages in Carotid Atherosclerotie Plaques: Studies in Patients Undergoing Endarterectomy. Arterioscler Thromb Vase Biol, 2015, 35: 1696-1730.
  • 9Anderson C J, Dehdashti F, Cutler PD, et al. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2001, 42: 213-221.
  • 10Lewis JS, Lewis MR, Cutler PD, et al. Radiotherapy and dosimetry of 64Cu-TETA-Tyr3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model. Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, 5: 3608-3616.

同被引文献1

引证文献1

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部